Retrospective Assessment of Visceral Leishmaniasis in Saptari District, Nepal
Abstract
Visceral leishmaniasis (VL) is still posing a major public health threat in Terai belt of Nepal, mainly bordering Bihar State of India. In order to assess the epidemiological, diagnostic and treatment trends of visceral Leishmaniasis in Saptari district, a retrospective study was carried out assessing the available data of last five years (2007-2012). Epidemiologically, VL cases seem to be in declining trend during last five years in Saptari district. The highest prevalence was recorded in the year 2007 (31.5%) VL cases, which was reduced by 3.5% in 2012. Similarly, Diagnosis practice adopted in different treatment centres of Saptari district showed rK-39 as mostly practiced method compared to bone marrow aspiration technique, both in laboratory as well as in field condition. Therapeutic trend administered in VL cases showed that majority of the patients were treated with Miltefosine with different drug dosage compared to SAG and Amphotericin B. Eventually the cure rate was found to maximum with Miltefosine as it was also used in patients with antimony resistant cases
References
Albrecht, H. 1998. Leishmaniasis new perspectives on an underappreciated opportunistic infection AIDS. 12: 2225-2226.
Bora, D. 1999. Epidemiology of Visceral leishmaniasis in India. Indian Journal of National Medicine. 12: 62-68
Bern, C, Hightower AW, Chowdhury, R., Ali, M. and Amann. J. 2005. Risk factors for kala-azar in Bangladesh. Emerging Infectious Disease.11: 655-662.
BPKIHS. 2010. Koirala Institute of Health Science. World Health Organization consultation on epidemiological information on disease burden due to kala-azar in Nepal.
Croft, S.L., Guerin, P.J., Olliaro, P., Sundar, S., Boelaert. M., Desjeux, P. et al. 2002. Visceral leishmaniasis: Current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infectious Disease. 2: 494-501.
Desjeux, P. 1992. Human leishmaniasis: epidemiology and public health aspects.World Health Statistics. 45: 267-275.
EDCD. 2012. Annual Report 2067/2068(2010/2011). Department of Health Service, Ministry of Health and Population, Kathmandu, Nepal.
Karamian, M., Motazedian, M.H. and Mehrabani, D. 2007. Leishmania major infection in a patient with visceral leishmaniasis treatment with Amphotericin B. Parasitological Research. 101: 1431-1434.
Pandey Basudev, Pun Sherbahadur, Kaneko Osamu, Pandey Kishor and Hirayama Kenji 2011. Expansion of visceral leishmaniasis to the western hilly part of Nepal. Annals of Journal of Tropical Medicine and Hygiene. 84(1): 107-108.
Rey, L.C., Martins, C.V., Ribeiro, H.B.and Lima, A.A. 2005. American visceral leishmaniasis (kalaazar) in hospitalized children from an endemic area. Reo d Jenerio Journal of Medicine. 81: 73-78.
Seaman, J.1993. Epidemic visceral leishmanisis in Sudan: a randomized trail of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. Journal of Infectious Disease. 168: 715-720.
Singh, S.P., Reddy, D.C., Rai, M. and Sundar, S. 2006. Serious underreporting of visceral leishmaniasis through passive case reporting in Bihar, India. Tropical Medicine and International Health. 11: 899-905.
Sundar, S., Agrawal, G., Rai, M., Makharia, M.K. and Murray, H.W.2001. Treatment of Indian visceral Lesihmaniasis with single or daily infusions of low dose liposomal Amphotericin B: randomized trail. British Medical Journal. 323: 419-422.
Sundar, S., Pai, K., Kumar, R., Pathak-Tripathi, K., Gam, A.A., Ray, M. et al.2001. Resistance to treatment in Kala-azar: speciation of isolates from northeast India. American Journal of Tropical Medicine and Hygiene .65: 193-196.
World Health Organization, 2010. The World Health Assembly Resolution on the control of leishmaniasis. Geneva, Switzerland.
World Health Organization, 2012. Leishmaniasis: Worldwide epidemiological and drug access update. Geneva, Switzerland.
Zijlstra, E. E., el-Hassan, A. M., Ismael, A. and Ghalib, H. W. 1994. Endemic kala-azar in eastern Sudan. A longitudinal study on the incidence of clinical and subclinical infection and post kala-azar dermal leishmaniasis. American Journal of Tropical Medicine and Hygiene. 51: 826-836
The Nepalese Journal of Zoology has a licensing policy that permits distribution, remixing, adaption, and build upon your work under a Creative Commons Attribution (CC-BY) 4.0 License. Authors retain the copyright of the contents published in NJZ and need to grant the right of first publication to the journal. It also allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., on their website) prior to and during the submission process (e.g., as a preprint), as it can lead to productive exchanges, as well as earlier and greater citation of the published work. However, authors need to enter into separate, additional contractual arrangements with NJZ for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in an institutional book), with an acknowledgment of its initial publication in this journal.
